Cellebrite: Pertento reports 5.2% passive stake

Pertento Partners LLP, Pertento Advisors LLC, and Eduardo Marques each reported a 5.2% passive stake in Cellebrite DI Ltd. (CLBT), owning 13,164,696 shares with shared voting and dispositive power. The shares are directly owned by advisory clients, with no beneficial ownership claimed beyond pecuniary interest.

Original reporting
Published Oct 9, 2026, 10:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 1:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CLBT
Neutral
medium confidence
Mentioned
$CLBT
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The disclosure adds transparency but is unlikely to move the stock significantly.

02

Market read

Low relevance; routine ownership filing with modest stake.

03

Timing

on filing day

Relevance 4/10Novelty 4/10Timing: on filing day

Background

Cellebrite (CLBT) filed a Schedule 13G showing Pertento Partners and advisors own 5.2% of its shares on a passive basis.

Company-level read

Ticker impact

$CLBTNeutralMedium confidence
Context

Cellebrite disclosed a 5.2% passive stake via a Schedule 13G filing, indicating new beneficial ownership.

Expected impact

likely minimal impact as the passive stake is disclosed

Evidence & confidence

A 5.2% passive stake is not large enough to shift control or trigger significant trading activity.

Market effects

none

US

low

Key entities

  • Cellebrite DI Ltd.

    US-listed digital forensics company

  • Pertento Partners LLP

    Advisory client holding passive stake

Related articles

$CLBTHighAI 8/10

Cellebrite DI Ltd. (CLBT): Financial results for Q3 2026

Cellebrite DI Ltd. (CLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Cellebrite Reports Third-Quarter 2026 Results Third-Quarter ARR Growth of 20% and TTM Free Cash Flow Margin of 31% Net income of $26.7 million; Non-GAAP net income of $45.6 million and adjusted EBITDA of $53.6 million, 36% adjusted EBITDA margin TYSONS CORNER, VA and

$CLBTHigh

Cellebrite Reports Third-Quarter 2026 Results

Cellebrite reported Q3 2026 results with ARR up 20% to $528.5M, revenue up 18% to $149M, and adjusted EBITDA of $53.6M. CEO Shiv Ramji highlighted strong international and U.S. Federal performance, and raised 2026 adjusted EBITDA outlook to $163M-$166M. The company also announced plans to redomicile in the U.S. and progress with its Genesis AI solution.

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.